scPharmaceuticals Inc. Logo

scPharmaceuticals Inc.

Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.

SCPH | US

Overview

Corporate Details

ISIN(s):
US8106481059
LEI:
Country:
United States of America
Address:
25 BURLINGTON MALL ROAD, SUITE 203, 1803 BURLINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

scPharmaceuticals Inc. is a commercial-stage pharmaceutical company, operating as a subsidiary of MannKind Corporation, focused on developing and commercializing patient-centric treatments for cardiorenal diseases. The company specializes in drug-device combinations that facilitate subcutaneous drug delivery, aiming to improve patient outcomes and shift care from clinical settings to the home. Its flagship product, FUROSCIX®, is a proprietary formulation of furosemide delivered via an auto-injector for treating congestion in patients with heart failure and, as of 2025, chronic kidney disease. The company's strategy centers on creating value-based solutions that reduce the burden of care and enhance quality of life for patients with cardiovascular and renal conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all scPharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for scPharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for scPharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CervoMed Inc. Logo
Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.
United States of America
CRVO
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark
CESSA
CG Invites Co., Ltd. Logo
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
South Korea
083790
CG Oncology, Inc. Logo
Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
United States of America
CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
South Korea
261780

Talk to a Data Expert

Have a question? We'll get back to you promptly.